{"disease":{"id":"third-degree-burns","name":"third degree burns","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"mafenide","indication_name":"Adjunctive therapy for second- and third-degree burns","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfamylon","generic_name":"MAFENIDE","company_name":"Rising","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 12","drug_class":"Methylated Sulfonamide Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"silver","indication_name":"third degree burns","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silver Sulfadiazine","generic_name":"SILVER","company_name":"King Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":38,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03113747","title":"Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"A.A. Partners, LLC","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}